Breaking Research News from Breastcancer.org
Comments
-
Poor Quality of Life Linked to Stopping Hormonal Therapy Treatment Early
July 1, 2021
Women who report worse quality of life factors, such as poor physical well-being, poor social well-being, and a history of depression, are more likely to stop hormonal therapy early. Read more...0 -
Women With BRCA1 Gene Mutation Have Fewer Eggs in Ovaries
July 1, 2021
Women with a mutation in the BRCA1 gene likely have fewer eggs in their ovaries than the average woman, which may shorten their window of opportunity to have children. Read more...0 -
Study Finds No Link Between Fertility Treatments and Breast Cancer Risk
July 1, 2021
Medicines commonly used to stimulate the ovaries to release eggs during fertility treatment don't seem to increase the risk of developing breast cancer. Read more...0 -
More Than 2 Years of Bisphosphonates for Early-Stage Breast Cancer Doesn't Offer More Benefits
July 2, 2021
Receiving 3 to 5 years of bisphosphonate treatment after surgery and chemotherapy for early-stage breast cancer doesn't improve survival any more than receiving 2 years of bisphosphonate treatment. Read more...0 -
Chemotherapy for Breast Cancer Doesn't Seem To Increase Risk of COVID-19 Infection or Death
July 7, 2021
Women treated with chemotherapy for breast cancer were no more likely to be infected with COVID-19 or die from COVID-19 than women treated with other medicines that don't weaken the immune system. Read more...0 -
Breast Cancer Death Rate Decreases in Florida, but Still Highest for Black Women
July 8, 2021
Breast cancer death rates decreased among all racial and ethnic groups from 1990 to 2015 in Florida, but Black women were still twice as likely to die from breast cancer as white women. Read more...0 -
Breast Cancer Screening Declined Sharply When Pandemic Started
July 23, 2021
A new study by the Centers for Disease Control and Prevention echoes the results of other studies: Breast cancer screening rates dropped dramatically at the beginning of the COVID-19 pandemic, especially among women of certain racial and ethnic groups. Read more...0 -
FDA Approves Keytruda for Early-Stage Triple-Negative Breast Cancer
July 27, 2021
The U.S. Food and Drug Administration (FDA) has approved Keytruda plus chemotherapy before surgery, followed by Keytruda alone after surgery to treat early-stage triple-negative breast cancer with a high risk of recurrence. Read more...0 -
Keytruda Before and After Surgery Improves Outcomes in Early-Stage Triple-Negative Breast Cancer
July 27, 2021
The immunotherapy medicine Keytruda plus chemotherapy before surgery and Keytruda alone after surgery improved event-free survival better than chemotherapy alone in women diagnosed with early-stage triple-negative breast cancer. Read more...0 -
Guidelines Help Oncologists Provide Individualized Palliative Care for People Diagnosed With Metastatic Breast Cancer
August 3, 2021
General oncologists have received new specific, practical recommendations on how to offer individualized palliative care to people diagnosed with metastatic breast cancer. Read more...0 -
After 5 Years of Hormonal Therapy, 2 More Years of Arimidex Offers Same Benefits As 5 More Years for Postmenopausal Women With Early-Stage Breast Cancer
August 6, 2021
After taking 5 years of hormonal therapy following surgery, postmenopausal women diagnosed with early-stage hormone-receptor-positive breast cancer got the same benefits from taking 2 more years of Arimidex as they did from taking 5 more years, with fewer side effects. Read more...0 -
Mods - Palliative Care guidelines are really important. Thanks for posting.
0 -
Treatment Break From Extended Femara Doesn't Affect Survival
August 17, 2021
Survival rates were the same in postmenopausal women diagnosed with early-stage hormone-receptor-positive breast cancer whether they took a short treatment break during extended adjuvant hormonal therapy with Femara or took Femara continuously for 5 years after previously taking hormonal therapy for an initial 5 years. Read more...0 -
Genentech Withdraws Breast Cancer Indication From Tecentriq
August 28, 2021
On Aug. 27, 2021, Genentech announced it is voluntarily withdrawing the breast cancer indication from the immunotherapy medicine Tecentriq in the United States. Read more...0 -
Chemo Brain Less Likely in Women Who Exercise
August 31, 2021
Women diagnosed with breast cancer who exercised before, during, and after chemotherapy were less likely to have chemo brain. Read more...0 -
Women With Breast Cancer Gene Mutation Have Same or Better Survival as Women Without Mutation
September 8, 2021
Women with a genetic mutation linked to a higher cancer risk who are diagnosed with breast cancer or ovarian cancer and receive chemotherapy treatment have the same or better survival rates as women who don't have a genetic mutation linked to higher risk. Read more...0 -
Six Months After Second Pfizer Vaccine Dose, People With Solid Tumors Have Same COVID-19 Antibody Levels as People Without Cancer
September 9, 2021
Six months after receiving their second dose of the Pfizer COVID-19 vaccine, people diagnosed with solid tumor cancers had about the same antibody levels as people who hadn't been diagnosed with cancer. Read more...0 -
Adding Surgery to Treatment Plan Offers Better Survival for Certain Women Diagnosed With Stage IV Breast Cancer
September 20, 2021
A combination of surgery and systemic therapy can improve survival more than systemic therapy alone for women diagnosed with stage IV breast cancer with known hormone receptor and HER2 status. Read more...0 -
Supervised Exercise Safe for People With Bone Metastases
September 20, 2021
People diagnosed with metastatic cancer that has spread to the bones can safely participate in supervised exercise programs, according to a review of 17 studies. Read more...0 -
Adding Carboplatin to Chemotherapy Before Surgery Improves Early-Stage Triple-Negative Breast Cancer Outcomes
September 20, 2021
Adding carboplatin (brand name: Paraplatin) to the standard neoadjuvant chemotherapy regimen for early-stage triple-negative breast cancer improved event-free survival. Read more...0 -
Enhertu Dramatically More Effective Than Kadcyla as Second Treatment for Metastatic HER2-Positive Breast Cancer
September 22, 2021
Enhertu more than doubled the 12-month progression-free survival rate than Kadcyla in people diagnosed with metastatic HER2-positive breast cancer that had been previously treated. Read more...0 -
After 2-3 Years of Tamoxifen, 5 Years of Femara Offers More Benefits Than 2-3 Years
September 30, 2021
After taking tamoxifen for 2 to 3 years following surgery, postmenopausal women diagnosed with early-stage hormone-receptor-positive breast cancer had a better survival rate from taking 5 years of Femara rather than 2 to 3 years of Femara. Read more...0 -
Adding Kisqali to Femara Improves Overall Survival for Postmenopausal Women With Advanced-Stage Hormone-Receptor-Positive HER2-Negative Breast Cancer
October 5, 2021
Adding Kisqali to Femara as a first treatment for advanced-stage hormone-receptor-positive HER2-negative breast cancer in postmenopausal women improved overall survival by more than 1 year. Read more...0 -
Experimental Vic-Trastuzumab Duocarmazine Better Than Doctors' Treatment Choices for Pre-treated Advanced-Stage HER2-Positive Breast Cancer
October 5, 2021
The experimental targeted therapy medicine vic-trastuzumab duocarmazine improved progression-free survival and overall survival more than doctors' treatment choice for people diagnosed with advanced-stage HER2-positive breast cancer that had been previously treated with anti-HER2 medicine. Read more...0 -
Adding Keytruda to Chemotherapy Improves Overall Survival in Metastatic, Strongly PD-L1-Positive Triple-Negative Breast Cancer
October 5, 2021
Adding the immunotherapy medicine Keytruda to chemotherapy improved overall survival more than chemotherapy alone in people diagnosed with metastatic triple-negative, strongly PD-L1-positive breast cancer, according to the KEYNOTE-355 study's final results. Read more...0 -
Long-Term Side Effects Reduce Quality of Life Years After Cancer Diagnosis
October 5, 2021
About 4 years after being diagnosed with cancer, 14% of disease-free survivors were dissatisfied with the care they received for ongoing, long-term side effects of cancer treatment. Read more...0 -
Risk of Triple-Negative Breast Cancer Nearly Three Times Higher for Black Women Than for White Women
October 12, 2021
Black women are 2.7 times more likely to be diagnosed with triple-negative breast cancer than white women, according to a study of risk factors in more than 198,000 women. Read more...0 -
Verzenio Approved To Treat Hormone-Receptor-Positive Early-Stage Breast Cancer With High Risk of Recurrence
October 13, 2021
The FDA approved Verzenio in combination with either tamoxifen or an aromatase inhibitor after surgery to treat early-stage hormone-receptor-positive HER2-negative node-positive breast cancer with high recurrence risk and a Ki-67 score of 20% or greater. Read more...0 -
Better Support During Radiation Treatment Improves Breast and Lung Cancer Survival Rates for Black and White Women
October 30, 2021
Identifying and offering solutions for obstacles that kept people from completing radiation therapy for early-stage breast and lung cancer improved outcomes and seemed to eliminate the difference in survival rates between Black and white people. Read more...0 -
Pfizer, Moderna COVID-19 Vaccines Less Effective in Immunocompromised People, But Help Avoid Hospitalization
November 9, 2021
The Pfizer and Moderna COVID-19 vaccines help keep people with weakened immune systems out of the hospital if they are infected, but don't offer as much protection as they do in people with fully functioning immune systems. Read more...0
